Dear Sir,
Watanabe et al. examined the impact of different targeted temperatures on the neurological outcomes for patients with out-of-hospital cardiac arrest (OHCA). Data were retrieved from the Japanese Association for Acute Medicine (JAAM)-OHCA registry, a prospective database in Japan. The patients received targeted temperature management (TTM) after undergoing extracorporeal cardiopulmonary resuscitation (ECPR). The study contained two groups of patients: those receiving normothermic TTM (n-TTM) (35–36 °C) and those receiving hypothermic TTM (h-TTM) (32–34 °C). No differences in 30-day favorable neurological outcomes [OR (95% CI) 1.01 (0.67–1.54)] or survival [OR (95% CI) 1.05 (0.76–1.46)] were observed between the two groups [
1].
In Japan, two studies on the use of ECPR for OHCA have recently been reported. The first is a retrospective observational study (
N = 890, 2014–2019) that used the JAAM-OHCA registry and included all kinds of OHCA patients [
1]. The second is a retrospective registry study (
N = 1644, 2013–2018) with the largest number of ECPR patients in the world; it is known as the Study of Advanced life support for Ventricular fibrillation with Extracorporeal circulation in Japan (SAVE-J II) [
2].
Regarding the use of TTM after ECPR in Japan, the principal philosophy was speculated from a questionnaire survey distributed to medical institutions that participated in the SAVE-J II study [
3]. According to the survey results, the targeted temperature of 33–34 °C was initiated in 83.3% of institutions as a first-line therapy. In contrast, the targeted temperature of 35–36 °C was initiated in only 11.1% of institutions. Thus, in Japan, especially before the results of TTM2 trial were published in 2021 [
2], hypothermia at 33–34 °C was the main targeted temperature, and normothermia was supposed to be initiated only for patients with severe conditions such as hemodynamic instability, bleeding complications, and highly predicted poor prognosis comprehensively evaluated by physicians. Because of the uncontrolled bias (physician’s decision), it is highly suspected that hypothermia is associated with favorable neurological outcomes compared with normothermia even when bias was well controlled. On the basis of the SAVE-J II trial, we are now preparing for a detailed analysis of the association between the difference in targeted temperatures in OHCA patients receiving ECPR and the neurological outcomes.
The difference observed between the JAAM-OHCA registry (the current study) and SAVE-J II is mainly due to the difference in the included patients. The first included OHCA patients with all causes of arrest [
1], whereas noncardiac conditions were excluded in the second [
2]. According to another study using the JAAM-OHCA registry, the noncardiac cause was estimated to account for ~ 50% of cases [
4]. However, noncardiac conditions, such as acute aortic dissection/aortic aneurysm, primary hypothermia, primary cerebral disorder, infection, drug intoxication, trauma, suffocation, and drowning, have different clinical outcomes and targeted temperatures [
5]. Cardiac or noncardiac patients can almost be identified at the initiation of TTM; therefore, the results of the subgroup analysis may have contributed to the clinical decision for the targeted temperature.
Acknowledgements
Not applicable.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.